Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of the 74 patients with HGSC

From: LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway

 Mean or numberRange or percentage
Age at diagnosis (years)53.41 ± 9.2934–76
 Menopausal status
  Pre-menopausal2331.1%
  Post-menopausal5168.9%
 Family history of cancer
  Yes68.1%
  No6891.9%
Preoperative CA125 levels (IU/ml)2005.42 ± 3137.7115–17,980
 FIGO stage
  Stage I1013.5%
  Stage II68.1%
  Stage III5270.3%
  Stage IV68.1%
 Lymphatic metastasis
  Yes2837.8%
  No4662.2%
 Cytoreductive surgery
  Residual tumor ≤ 1 cm5371.6%
  Residual tumor > 1 cm2229.7%
 Current status
  NED2533.8%
  AWD1925.7%
  DOD3040.5%
  1. HGSC high-grade sercous carcinoma, FIGO International Federation of Gynecology and Obstetrics, NED no evidence of disease, AWD alive with disease, DOD die of disease